Asymchem Labs reports double-digit revenue and profit growth

Asymchem Laboratories (Tianjin) (SZSE:002821) announced a 10.10% year-over-year increase in revenue for the first quarter of 2025, reaching CNY 1.54 billion. Net profit attributable to shareholders grew by 15.83% to CNY 326.61 million. The company attributed its performance to a resilient global pharmaceutical supply chain and strategic cost management measures. Emerging business segments such as peptides, oligonucleotides, and ADCs experienced substantial growth, with revenue increasing by over 80%. Basic and diluted earnings per share both stood at CNY 0.89, and the weighted average return on equity was 1.92%. Asymchem's total assets reached CNY 19.45 billion by the end of the reporting period, while shareholders' equity was CNY 17.18 billion.